Late-Breaking Clinical Trial Results at the VEINS 2026

Cyanoacrylate Closure Durability in C6 Disease

The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine through education and research, announced results from late-breaking clinical trials presented at The VEINS 2026 conference, held at Bellagio Las Vegas. According to a report by PR Newswire M&A on Sunday, Oct. 4, 2026, the scientific sessions held on Saturday, October 3, and Sunday, October 4, unveiled new data advancing the understanding and treatment of venous disease. The VEINS conference focuses on the diagnosis, intervention, and management of venous disorders across the vascular spectrum.

Among the presentations, Manj Gohel shared 24-month secondary outcomes from a prospective, single-arm observational study evaluating cyanoacrylate closure for saphenous ablation in chronic venous disease patients with C6 disease. Conducted across 17 sites in the United States and Europe, the study treated 125 participants using the VenaSeal closure system alongside wound and compression therapy. Results showed an ulcer healing rate of 88.1% through the 24-month visit, with a median time to healing of 92 days within a 95% confidence interval of 74 to 137 days. The recurrence rate through 24 months reached 22.9%, while mean ulcer-free time was 487.38 days with a standard deviation of 260.16 days. The probability of anatomic vein closure stood at 78.0% at 24 months. Investigators reported no device-related events after 6 months following adjudication of hypersensitivity, phlebitis, granuloma, and ablation-related thrombus extension. Furthermore, sub-ulcer sclerotherapy was utilized in 21.6% of participants, corresponding to 27 out of 125 individuals, at the time of the index procedures.

Percutaneous Ligation and Stent Safety Data

Steve Elias presented the interim 6-month results of the BERG02 study, a single-center, nonrandomized trial examining the VEnice percutaneous device for treating superficial and perforator vein incompetence. The trial enrolled 22 patients with symptomatic great saphenous vein incompetence and CEAP class C2 or higher. The patient cohort had a mean age of 49.3 years and included 20 women. Procedures were performed by four vascular surgeons, three of whom lacked prior device experience, treating 22 great saphenous veins, three anterior saphenous veins, and 11 perforator veins with a mean proximal great saphenous vein diameter of 8.44 millimeters and a standard deviation of 2.57 millimeters. Technical success reached 100%, and deployment time ranged from 1 to 2 minutes per clip. No device-related serious adverse events or procedure-related complications occurred within 30 days. At 1 month, 22 of 22 great saphenous veins and 10 of 11 perforator veins remained closed. Preliminary 6-month findings demonstrated 100% closure in the eight patients with great saphenous vein results presented and in the three patients with perforator results presented.

In a separate presentation, Paul Gagne shared early 30-day results from a real-world registry of the Abre Venous Stent System for symptomatic iliofemoral venous outflow obstruction. Utilizing the Medtronic Product Surveillance Registry platform, the global prospective study enrolled 151 patients across 15 sites in Europe and the USA between June 2024 and September 2025. The patient demographic comprised 72.8% females with a mean age of 50.6 years and a standard deviation of 17.4 years, treated for nonthrombotic iliac vein lesions in 74.3% of cases, post-thrombotic syndrome in 21.1%, acute deep vein thrombosis in 3.3%, and other conditions in 1.3%. Pelvic venous disorder was present in 45.7% of patients. Stent fractures were reported in 0 patients, and target lesion revascularization occurred in 1 patient, representing 0.7%, through 30 days. Patients treated with larger stent diameters of 18 to 20 millimeters reported larger increases in immediate pain that decreased and aligned with the overall cohort by day 30, matching trends where infrastructure adjustments often reveal initial operational spikes before stabilizing.

Thrombolysis and C-TRACT PTS Findings

Wissam A. Jaber presented an interim analysis of 150 participants in the RAPID-PE study, a prospective, multicenter, single-arm trial evaluating on-the-table mechanically channeled thrombolysis using the THROMBOLEX device for acute intermediate-risk pulmonary embolism. Participants had a mean age of 65.2 years, a mean baseline right ventricular to left ventricular ratio of 1.40, and bilateral pulmonary embolism in 93.3% of cases, totaling 140 patients. The 7-day primary composite occurred in 1 out of 150 participants, or 0.7%, while major bleeding within 72 hours also occurred in 1 out of 150 participants, or 0.7%. No ischemic or hemorrhagic strokes were reported through 30 days. Device- or procedure-related serious adverse events occurred in 2 out of 150 participants, or 1.3%, through discharge. Post-treatment intensive care unit care was provided to 15 out of 150 patients, representing 10.0%, with 7 out of 150 patients, or 4.7%, requiring intensive care due to their clinical condition. Within 30 days, recurrent pulmonary embolism occurred in 4 out of 150 patients, or 2.7%, and rehospitalization occurred in 17 out of 150 patients, or 11.3%, with a median hospital stay of 2.96 days from emergency department arrival to discharge order.

Suresh Vedantham presented 24-month results from the NIH-sponsored C-TRACT randomized trial, evaluating the effects of endovascular therapy on health-related quality of life in patients with moderate or severe post-thrombotic syndrome and iliac vein obstruction. Out of 225 randomized patients across 29 U.S. centers, the first 197 patients self-reported their quality of life. At 24 months, quality of life measured by VEINES-QOL scale points was higher in the endovascular therapy group at 63.5 with a standard error of 3.0, compared to 53.0 with a standard error of 2.8 for the no-endovascular therapy group, yielding an adjusted difference of 10.5 within a confidence interval of 4.6 to 16.4 and a p-value below 0.001. Medical Outcomes SF-36 Physical Component Summary Scale points reached 56.3 with a standard error of 1.8 for endovascular therapy versus 51.2 with a standard error of 1.7 for no-endovascular therapy, showing an adjusted difference of 5.2 within a confidence interval of 1.5 to 8.9 and a p-value of 0.006. Endovascular therapy also improved venous symptoms with VEINES-Sym points of 61.4 with a standard error of 3.1 versus 54.1 with a standard error of 3.0, showing an adjusted difference of 7.3 within a confidence interval of 1.0 to 13.6 and a p-value of 0.02. Through 24 months, occurrences of symptomatic recurrent venous thromboembolism were 2.1% for endovascular therapy and 7.1% for no-endovascular therapy, any bleeding was 15.5% versus 8.1%, major bleeding was 4.1% versus 2.0%, and death was 2.1% versus 3.0%, showing no statistically significant differences between groups. These findings arrive as clinical data milestones continue to shape therapeutic benchmarks across medical specialties. Andrew Holden concluded the presentations by sharing 1-year functional outcomes and quality of life data for pulmonary embolism after mechanical thrombectomy across 1,000 prospective patients.